公开(公告)号：US07166695B2

公开(公告)日：2007-01-23

申请号：US10934841

申请日：2004-09-02

申请人： Alexander Krantz ,  Wolin Huang ,  Arthur M. Hanel ,  Darren L. Holmes ,  Dominique P. Bridon

发明人： Alexander Krantz ,  Wolin Huang ,  Arthur M. Hanel ,  Darren L. Holmes ,  Dominique P. Bridon

IPC分类号： C07K7/06

CPC分类号： A61K49/0021 ,  A61K38/00 ,  A61K47/62 ,  A61K47/6901 ,  A61K49/0043 ,  A61K49/0056 ,  C07K14/665

摘要： Methods and compositions are provided for identifying compounds having affinity or complementarity to a target molecule. Compounds according to the invention may be described by the formula E-Ca—R—Cb-A, wherein E is a therapeutic or diagnostic agent, R is a reactive group, Ca and Cb are connector groups between E and R and between R and A, respectively, and A is an affinity group comprising the sequence F-1-Y-E-E. Compounds according to the invention may be used for labeling the target molecule, particularly where the target molecule is naturally found in a complex mixture, such as a physiological fluid, like blood. By affinity labeling in vivo, the lifetime of physiologically active entities can be greatly enhanced by becoming bound to long-lived blood components. The covalently bound entity may also serve as an antagonist or agonist of a particular binding protein or as an enzyme inhibitor.

摘要翻译： 提供了用于鉴定与靶分子具有亲和力或互补性的化合物的方法和组合物。 根据本发明的化合物可以用下式描述：其中E是治疗剂或诊断剂，R是反应性基团，C < 分别是E和R之间以及R和A之间的连接器组，A是包含序列F-1 -YEE的亲和基团。 根据本发明的化合物可以用于标记靶分子，特别是当目标分子天然存在于复杂混合物如生理液体如血液中时。 通过体内亲和标记，生理活性实体的寿命可以通过与长寿命的血液成分结合而大大增强。 共价结合的实体也可以用作特异性结合蛋白的拮抗剂或激动剂或作为酶抑制剂。

公开(公告)号：US06821949B2

公开(公告)日：2004-11-23

申请号：US10287892

申请日：2002-11-04

申请人： Dominique P. Bridon ,  Benoit L'Archeveque ,  Alan M. Ezrin ,  Darren L. Holmes ,  Anouk Leblanc ,  Serge St. Pierre

发明人： Dominique P. Bridon ,  Benoit L'Archeveque ,  Alan M. Ezrin ,  Darren L. Holmes ,  Anouk Leblanc ,  Serge St. Pierre

IPC分类号： A61K3800

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K47/643 ,  C07K14/57563 ,  C07K14/605 ,  C12N2740/16122

摘要： Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.

摘要翻译： 公开了改进的促胰岛素肽。 修饰的促胰岛素肽能够形成肽酶稳定的促胰岛素肽。 修饰的促胰岛素肽能够与一种或多种血液成分形成共价键以形成缀合物。 缀合物可以在体内或离体形成。 施用修饰的肽以治疗患有糖尿病和其他相关疾病的人。

公开(公告)号：US5624797A

公开(公告)日：1997-04-29

申请号：US472597

申请日：1995-06-07

申请人： Dominique P. Bridon ,  Isaac S.-Y. Sze, deceased ,  David J. Daghfal ,  Keeve D. Jaffe ,  Tracey L. Colpitts

发明人： Dominique P. Bridon ,  Isaac S.-Y. Sze, deceased ,  David J. Daghfal ,  Keeve D. Jaffe ,  Tracey L. Colpitts

摘要： HIV-1 peptides having at least one point mutation between position 593 and 611 of the HIV-1 gp160 amino acid sequence. The point mutation either is at position 604 or 610, or both positions. Immunoassays which utilize these peptides are provided, as well as, diagnostic test kits which contain these peptides.